Loading...
•
Sep 30, 2023
Bausch Health Q3 2023 Earnings Report
Bausch Health reported solid third-quarter performance with year-over-year revenue growth in all segments and provided updated full-year revenue and Adjusted EBITDA guidance.
Key Takeaways
Bausch Health announced its third-quarter 2023 financial results, with revenue of $2.24 billion, up 9% on both a Reported and Organic basis. All segments showed year-over-year revenue growth. The company's Adjusted EBITDA was $830 Million, up 8%. They also received FDA approval for CABTREOTM and provided updated full-year Revenue and Adjusted EBITDA guidance.
Revenue of $2.24 billion, up 9% on both a Reported and Organic basis
Year-over-year revenue growth in all segments on both a Reported and Organic Basis
Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) of $830 Million, up 8%
Received U.S. Food and Drug Administration ( FDA ) approval for CABTREOTM (IDP-126)
Revenue by Segment
Forward Guidance
The Company updated its full-year revenue and Adjusted EBITDA guidance:
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...